NCT00801905|TerminatedPhase 2
Study Stopped
undefined
Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation
NEPAF
Loading search results
Sponsor study identifier
Secondary identifiers
interventional
50
1 country
2
Study Start
August 2008
Actual (reported)Primary Completion
December 2008
Actual (reported)Study Completion
March 2009
Actual (reported)The purpose of this study is to determine whether topical nepafenac (qid) is effective in preventing and treating macular thickening related pan-retinal photocoagulation in patients with diabetic retinopathy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2009
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2008
Actual (reported)December 2008
Actual (reported)December 3, 2008
Actual (reported)December 4, 2008
Actual (reported)March 2009
Actual (reported)Central macular thickening
2 weeks after each laser session and 1 and 2 months after last laser session
Best corrected visual acuity
2 weeks after each laser session, 1, 2 and 3 months after pan-retinal photocoagulation is completed
Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
Asociación Para Evitar la Ceguera en México I.A.P.
Mexico City, 004030, Mexico
Asociacion para Evitar la Ceguera en Mexico I.A.P.
Mexico City, 04030, Mexico
Dulce O Rascon-Vargas, Fellow
Asociación Para Evitar la Ceguera en México I.A.P.
Guadalupe Cervantes-Coste
Asociación Para Evitar la Ceguera en México I.A.P.
Jans Fromow-Guerra
Asociación Para Evitar la Ceguera en México I.A.P.
50 participants (actual enrollment reported by the registry).
First Submitted
December 3, 2008
First Posted
December 4, 2008
Study Start
August 2008
Actual (reported)Avastin for Post-photocoagulation Macular Edema
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
December 2008
Actual (reported)Study Completion
March 2009
Actual (reported)Last Updated
May 30, 2024
Record last verified: 2024-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: